These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 27868466

  • 41. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.
    Lancet; 1999 Jul 10; 354(9173):116-9. PubMed ID: 10408487
    [Abstract] [Full Text] [Related]

  • 42. Anti-tuberculosis drug resistance pattern among pulmonary tuberculosis patients with or without HIV infection in Mwanza, Tanzania.
    Range N, Friis H, Mfaume S, Magnussen P, Chanualucha J, Kilale A, Mugomela A, Andersen AB.
    Tanzan J Health Res; 2012 Oct 10; 14(4):243-9. PubMed ID: 26591721
    [Abstract] [Full Text] [Related]

  • 43. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE, Chirgwin KD, Nelson ET, Matts JP, Sepkowitz KA, Benson CA, Perlman DC, El-Sadr WM.
    Int J Tuberc Lung Dis; 1999 Apr 10; 3(4):337-43. PubMed ID: 10206505
    [Abstract] [Full Text] [Related]

  • 44. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis.
    Zhang R, Xi X, Wang C, Pan Y, Ge C, Zhang L, Zhang S, Liu H.
    PLoS One; 2018 Apr 10; 13(7):e0201025. PubMed ID: 30024982
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.
    Sharma SK, Katoch K, Sarin R, Balambal R, Kumar Jain N, Patel N, Murthy KJR, Singla N, Saha PK, Khanna A, Singh U, Kumar S, Sengupta A, Banavaliker JN, Chauhan DS, Sachan S, Wasim M, Tripathi S, Dutt N, Jain N, Joshi N, Penmesta SRR, Gaddam S, Gupta S, Khamar B, Dey B, Mitra DK, Arora SK, Bhaskar S, Rani R.
    Sci Rep; 2017 Jun 13; 7(1):3354. PubMed ID: 28611374
    [Abstract] [Full Text] [Related]

  • 46. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.
    Daley P, Jagannathan V, John KR, Sarojini J, Latha A, Vieth R, Suzana S, Jeyaseelan L, Christopher DJ, Smieja M, Mathai D.
    Lancet Infect Dis; 2015 May 13; 15(5):528-34. PubMed ID: 25863562
    [Abstract] [Full Text] [Related]

  • 47. Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis.
    Kang MW, Kim HK, Choi YS, Kim K, Shim YM, Koh WJ, Kim J.
    Ann Thorac Surg; 2010 May 13; 89(5):1597-602. PubMed ID: 20417785
    [Abstract] [Full Text] [Related]

  • 48. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
    Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP.
    JAMA; 2008 Nov 12; 300(18):2153-60. PubMed ID: 19001626
    [Abstract] [Full Text] [Related]

  • 49. Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.
    Bekele A, Gebreselassie N, Ashenafi S, Kassa E, Aseffa G, Amogne W, Getachew M, Aseffa A, Worku A, Raqib R, Agerberth B, Hammar U, Bergman P, Aderaye G, Andersson J, Brighenti S.
    J Intern Med; 2018 Sep 12; 284(3):292-306. PubMed ID: 29696707
    [Abstract] [Full Text] [Related]

  • 50. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil SK.
    J Formos Med Assoc; 2016 Nov 12; 115(11):997-1003. PubMed ID: 26696497
    [Abstract] [Full Text] [Related]

  • 51. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
    van den Hof S, Tursynbayeva A, Abildaev T, Adenov M, Pak S, Bekembayeva G, Ismailov S.
    Int J Tuberc Lung Dis; 2013 Apr 12; 17(4):526-31. PubMed ID: 23485387
    [Abstract] [Full Text] [Related]

  • 52. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
    Rajasekaran S, Chandrasekar C, Mahilmaran A, Kanakaraj K, Karthikeyan DS, Suriakumar J.
    J Indian Med Assoc; 2009 May 12; 107(5):281-2, 284-6. PubMed ID: 19886382
    [Abstract] [Full Text] [Related]

  • 53. Comparative study of effect of Withania somnifera as an adjuvant to DOTS in patients of newly diagnosed sputum smear positive pulmonary tuberculosis.
    Kumar R, Rai J, Kajal NC, Devi P.
    Indian J Tuberc; 2018 Jul 12; 65(3):246-251. PubMed ID: 29933868
    [Abstract] [Full Text] [Related]

  • 54. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors.
    Banu Rekha VV, Balasubramanian R, Swaminathan S, Ramachandran R, Rahman F, Sundaram V, Thyagarajan K, Selvakumar N, Adhilakshmi AR, Iliayas S, Narayanan PR.
    Indian J Med Res; 2007 Nov 12; 126(5):452-8. PubMed ID: 18160750
    [Abstract] [Full Text] [Related]

  • 55. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis.
    Man MA, Nicolau D.
    Eur J Cardiothorac Surg; 2012 Jul 12; 42(1):e9-12. PubMed ID: 22531273
    [Abstract] [Full Text] [Related]

  • 56. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
    Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, Jang SH, Yoo KH, Jung KH, Kim KU, Choi SB, Ryu YJ, Chan Kim K, Um S, Kwon YS, Kim YH, Choi WI, Jeon K, Hwang YI, Kim SJ, Lee YS, Heo EY, Lee J, Ki YW, Shim TS, Yim JJ.
    Am J Respir Crit Care Med; 2013 Oct 01; 188(7):858-64. PubMed ID: 23927582
    [Abstract] [Full Text] [Related]

  • 57. Outcome correlation of smear-positivity for acid-fast bacilli at the fifth month of treatment in non-multidrug-resistant TB.
    Chien JY, Chen YT, Shu CC, Lee JJ, Wang JY, Yu CJ, Yang PC.
    Chest; 2013 Jun 01; 143(6):1725-1732. PubMed ID: 23288018
    [Abstract] [Full Text] [Related]

  • 58. The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
    Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.
    N Engl J Med; 2009 Jun 04; 360(23):2397-405. PubMed ID: 19494215
    [Abstract] [Full Text] [Related]

  • 59. Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients.
    Nikolaeva LG, Maystat TV, Masyuk LA, Pylypchuk VS, Volyanskii YL, Kutsyna GA.
    Drug Des Devel Ther; 2009 Feb 06; 2():87-93. PubMed ID: 19920896
    [Abstract] [Full Text] [Related]

  • 60. Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes.
    Mor Z, Goldblatt D, Kaidar-Shwartz H, Cedar N, Rorman E, Chemtob D.
    Int J Tuberc Lung Dis; 2014 Oct 06; 18(10):1195-201. PubMed ID: 25216833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.